MERLN strives for a leading position in the field of biomedical engineering by combining creative research with training of an interdisciplinary generation of scientists. MERLN’s activities operate at the interface of biology and engineering and aim at maximizing outreach at the level of public involvement, development and commercialization of research as well as venture-building. MERLN’s valorization vision is based on sharing of knowledge, an enabling commercialization infrastructure and venture-building ambition.
© 2020, University of New Hampshire, Used with permission.
Scientists at MERLN have an extensive network of collaborators within research institutions in and outside the Netherlands (among others institute partnership with HSCI -Harvard Stem Cell Institute and the CIRM Stem Cell Center of the University of California Irvine) as well as with a number of biomedical companies, including their own spin-off companies. MERLN is the founding partner institute of RegMed XB, a translational institute with an investment of EUR 250 million, which translates groundbreaking Regenerative Medicine technologies into commercial products and companies.
Commercialization of research concerns the value creation based on scientific knowledge developed at MERLN and translate this in competitive products, and biomedical start-up companies. MERLN actively strives to connect to the business community, KOL’s in our research fields and related industry. MERLN aims to provide an environment in which fundamental research results can be effectively translated into clinical application and manufacturing. We aim for a culture of public-private and international collaboration as well as interdisciplinary cooperation in which translational and entrepreneurial performance have comparative prestige (and career opportunities).
To coordinate MERLN’s valorisation mission, MERLN relies on Marianne van der Steen, Professor of Entrepreneurship in Healthcare and the Chief Business Development Officer of the MERLN Institute. Marianne is founding director of REGMED XB, a translational institute with an investment of EUR 250 million, which translates groundbreaking Regenerative Medicine technologies into commercial products and companies. Her research focus is on biomedical entrepreneurship, specifically on the scaling-up of ventures.